Intranasal Insulin for Weight Management During Smoking Cessation
Phase 2
Completed
- Conditions
- Tobacco Abstinence Syndrome
- Interventions
- Drug: Placebo
- Registration Number
- NCT02028871
- Lead Sponsor
- Ajna Hamidovic
- Brief Summary
This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
- smokers (>10 cig/day) for the past 1 year
- normosmic olfactory function
Exclusion Criteria
- previous/current use of insulin
- current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder
- current pregnancy (or lactation)
- lifetime history of endocrine disease
- excessive alcohol use (>25 standard units of alcohol/week)
- current use of illicit drugs
- current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic agent
- local infections, inflammation, structural abnormalities, or other nasal pathology
- current use of any medications administered intranasally, including intranasal steroids
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Intranasal Insulin First Intranasal Insulin Intranasal Insulin First, Placebo Second Placebo First Placebo Placebo First, Intranasal Insulin Second
- Primary Outcome Measures
Name Time Method Amount Eaten in Taste Test 90 minutes
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
UNM College of Pharmacy
🇺🇸Albuquerque, New Mexico, United States
UNM College of Pharmacy🇺🇸Albuquerque, New Mexico, United States